須田 剛生

須田 剛生

特任助教

学歴

1993年3月
桐朋学園高校卒業
2000年3月
信州大学医学部医学科卒業
2012年3月
東京医科歯科大学大学院医学博士課程修了

職経

2000年4月
東京医科歯科大学病院研修医
2001年6月
北信総合病院消化器内科 医員
2004年6月
土浦協同病院消化器内科 医員
2006年4月
東京医科歯科大学消化器内科 医員
2010年4月
取手総合病院消化器内科 医員
2012年9月
北海道大学消化器内科 特任助教

専門分野

  • 肝臓病診断・治療
  • ウイルス性肝炎

所属学会・資格

  • 日本内科学会 認定内科医
  • 日本消化器病学会 専門医
  • 日本消化器内視鏡学会 専門医
  • 日本肝臓学会 専門医・東部会評議員

趣味

サーフィン,ランニング

好きな言葉

意志あるところに道あり

受賞歴

  • 2011年 国際科学振興財団フォーラム研究奨励賞受賞
  • 2015年 Liver Forum in Kyoto 研究奨励賞
  • 2016年 肝臓病学会研究奨励症
  • 2017年 ウイルス肝炎財団研究奨励賞
  • 2018年 AASLD 2018 優秀ポスター賞(Poster of Distinction)
  • 2018年 G-Plus 優秀演題賞
  • 2019年 第11回Journal of Gastroenterology High Citation Award

研究費等

厚生労働省科学研究費補助金/日本医療研究開発機構(AMED)
  • 橋渡し研究シーズA 「IFN抵抗性解除に着目した新規抗HBV薬スクリーニング系を用いた既存薬repositioning の検討」研究代表者 2019年度
  • 肝炎等克服実用化研究事業 「次世代シークエンス技術を駆使したウイルスゲノム解析によるC型肝炎の病態解明と臨床応用」研究分担者(2013年度-2015年度)
  • 肝炎等克服実用化研究事業 「次世代シークエンス技術によるウイルス因子解析を基軸としたC型肝炎新規治療の病態解明と臨床応用」研究分担者(2016年度-2018年度)
  • 肝炎等克服実用化研究事業 「C型肝炎の新たな治療関連因子及び治癒後の病態進展・改善に関連する宿主因子等の同定を目指したゲノムワイド研究」研究分担者(2016年度-2018年度)
  • 肝炎等克服実用化研究事業 「C型肝炎のウイルス排除後に起こる病態に関する研究」研究分担者(2017年度-2019年度)
  • 肝炎等克服実用化研究事業 「C型肝炎ウイルス排除治療による肝硬変患者のアウトカムに関する研究開発」研究分担者(2019年度-2021年度)
  • 肝炎等克服実用化研究事業 「C型肝炎の直接作用型抗ウイルス薬による治療後の病態変化に影響を及ぼす宿主因子等の同定を目指したゲノムワイド研究」研究分担者(2019年度-2021年度)
文部科学省科学研究費補助金
  • 基盤研究(C) 「レポーターアッセイによる新規・大規模抗HBV薬スクリーニング系を用いた薬剤開発」研究代表者 (2019-2021年度)
  • 基盤研究(C) 「C末端欠損HBx遺伝子インテグレーションによる肝発癌・悪性化機構の検討」研究代表者 (2016年度―2018年度)
  • 若手研究(B) 「HCVキメラウイルス感染培養系を用いた薬剤耐性機序の解析」研究代表者 (2013年度-2014年度)
  • 基盤研究(C) 「HCVに対するカルニチンの抗ウイルス/抗脂肪化/抗酸化効果の基礎的・臨床的検討」研究分担者 (2015年度-2017年度)
  • 萌芽研究 「高速分子動力学法によるHCV抗ウイルス薬耐性化予測仮想アッセイシステムの構築」研究研究分担者 (2014年度-2015年度)
  • 基盤研究(B) 「肝硬変の組織学的進展・軽快を担う間質微小環境因子の包括的解析」 研究分担者 (2019年度-2021年度)
  • 挑戦的萌芽研究 「肝硬変の組織学的展を抑制する糖鎖修飾構造を標的とした薬剤開発系の構築」研究分担者 (2018 年度―2019年度)
  • 基盤研究(C)「B型肝炎ウイルスcccDNA排除を目指した新規抗ウイルス治療の開発」研究分担者 (2017-2019年度)
  • 基盤研究(B)「肝硬変の組織病態を修復する新規細胞薬物治療法の探索」研究分担者 (2016-2018年度)

論文(英文のみ)

  1. Takuya Sho, Goki Suda, Koji Ogawa, Megumi Kimura, Tomoe Shimazaki, Osamu Maehara, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Machiko Umemura, Naoki Kawagishi, Mitsuteru Natsuizaka, Masato Nakai, Kenichi Morikawa, Ken Furuya, Masaru Baba, Yoshiya Yamamoto, Tomoe Kobayashi, Takashi Meguro, Akiyoshi Saga, Takuto Miyagishima, Hideki Yokoo, Toshiya Kamiyama, Akinobu Taketomi, Naoya Sakamoto.
    Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real‐world setting.
    JGH open. 2019 in press
  2. Izumi T, Sho T, Morikawa K, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Kawagishi N, Umemura M, Shimazaki T, Kimura M, Nakai M, Suda G, Natsuizaka M, Ogawa K, Kudo Y, Nishida M, Ono K, Baba M, Furuya K, Sakamoto N.
    Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter.
    Hepatol Res. 2019 Jun 20. doi: 10.1111/hepr.13391. [Epub ahead of print]
  3. Maehara O, Ohnishi S, Asano A, Suda G, Natsuizaka M, Nakagawa K, Kobayashi M, Sakamoto N, Takeda H.
    Metformin Regulates the Expression of CD133 Through the AMPK-CEBPβ Pathway in Hepatocellular Carcinoma Cell Lines.
    Neoplasia. 2019 Jun;21(6):545-556. doi: 10.1016/j.neo.2019.03.007.
  4. Hirata K, Kuwatani M, Suda G, Ishikawa M, Sugiura R, Kato S, Kawakubo K, Sakamoto N.
    A Novel Approach for the Genetic Analysis of Biliary Tract Cancer Specimens Obtained Through Endoscopic Ultrasound-Guided Fine Needle Aspiration Using Targeted Amplicon Sequencing.
    Clin Transl Gastroenterol. 2019 Mar;10(3):e00022. doi: 10.14309/ctg.0000000000000022 in press
  5. Suda G, Hasebe C, Abe M, Kurosaki M, Itakura J, Izumi N, Uchida Y, Mochida S, Haga H, Ueno Y, Abe K, Takahashi A, Ohira H, Tsukuda Y, Furuya K, Baba M, Yamamoto Y, Kobayashi T, Inoue J, Terasita K, Ohara M, Kawagishi N, Izumi T, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection.
    J Gastroenterol. 2019 Feb 18. doi: 10.1007/s00535-019-01556-y.
  6. Masatsugu Ohara, Shunsuke Ohnishi, Hidetaka Hosono, Koji Yamamoto, Kohei Yuyama, Hideki Nakamura, Qingjie Fu, Osamu Maehara, Goki Suda and Naoya Sakamoto.
    Extracellular vesicles from amnion-derived mesenchymal stem cells ameliorate hepatic inflammation and fibrosis in rats.
    Stem Cells International. 2018 in press.
  7. Goki Suda, Masato Nakai, Takuya Sho, Megumi Kimura, Tomoe Shimazaki,Osamu Maehara, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara Machiko Umemura, Naoki Kawagishi, Masaru Baba, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, and Naoya Sakamoto for the NORTE Study Group.
    Successful retreatment with glecaprevir and pibrentasvir for genotype 1 or 2 HCV infected hemodialysis patients who failed to respond to treatment with HCV NS5A inhibitor and HCV protease inhibitor: a case report.
    Internal medicine. 2018 in press.
  8. Takuya Sho, Goki Suda, Megumi Kimura, Tomoe Shimazaki, Osamu Maehara, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara Machiko Umemura, Takaaki Izumi, Naoki Kawagishi, Masaru Baba2, Masato Nakai1, Mitsuteru Natsuizka1, Kenichi Morikawa1, Koji Ogawa1, and Naoya Sakamoto1 for the NORTE Study Group.
    Glecaprevir and pibrentasvir for Japanese patients with human immunodeficiency virus and genotype 3 hepatitis C virus coinfection: Report of 3 cases.
    Internal medicine. 2018 in press. (equal contribution)
  9. Kawagishi N, Suda G, Nakamura A, Kimura M, Maehara O, Suzuki K, Nakamura A, Ohara M, Izumi T, Umemura M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Kudo Y, Nishida M, Miyoshi H, Sakamoto N.
    Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
    PLoS One. 2018 Dec 21;13(12):e0209615. doi: 10.1371/journal.pone.0209615. eCollection 2018. (equal contribution)
  10. Goki Suda, Masayuki Kurosaki, Jun Itakura, Namiki Izumi, Yoshihito Uchida, Satoshi Mochida, Chitomi Hasebe, Masami Abe , Hiroaki Haga, Yoshiyuki Ueno, Ikuto Masakane, Kazumichi Abe, Atsushi Takahashi, Hiromasa Ohira, Ken Furuya, Masaru Baba, Yoshiya Yamamoto, Tomoe Kobayashi, Atsuhiko Kawakami, enichi Kumagai, Katsumi Terasita, Masatsugu Ohara, Naoki Kawagishi, Machiko Umemura, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, and Naoya Sakamoto for the NORTE Study Group.
    Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b Hepatitis C infection.
    J Gastroenterol. 2018 in press
  11. Masatsugu Ohara, Shunsuke Ohnishi, Hidetaka Hosono, Koji Yamamoto, Qingjie Fu, Osamu Maehara, Goki Suda, Naoya Sakamoto.
    Palmitoylethanolamide ameliorates carbon tetrachloride-induced liver fibrosis in rats.
    Frontiers in Pharmacology. 2018 in press
  12. Masatsugu Ohara, Koji Ogawa, Goki Suda, Megumi Kimura, Osamu Maehara, Tomoe Shimazaki, Kazuharu Suzuki, Akihisa Nakamura, Machiko Umemura, Takaaki Izumi, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Shunsuke Ohnishi and Naoya Sakamoto
    (equal contribution)
    Hepatology Communications. 2018 in press.
  13. Cai C, Koch B, Morikawa K, Suda G, Sakamoto N, Rueschenbaum S, Akhras S, Dietz J, Hildt E, Zeuzem S, Welsch C, Lange CM.
    Macrophage-Derived Extracellular Vesicles Induce Long-Lasting Immunity Against Hepatitis C Virus Which Is Blunted by Polyunsaturated Fatty Acids.
    Front Immunol. 2018 Apr 12;9:723. doi: 10.3389/fimmu.2018.00723. eCollection 2018.PMID:29706960
  14. Sho T, Suda G,, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, Uebayashi M, Terashita K, Kobayashi T, Tsunematsu I, Onodera M, Meguro T, Kimura M, Ito J, Umemura M, Izumi T, Kawagishi N, Ohara M, Ono Y, Nakai M, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group(Equal contribution).
    Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction.
    Hepatol Res. 2018 Jan 9. doi: 10.1111/hepr.13056. [Epub ahead of print] PMID:29316051
  15. Suda G, Ogawa K, Morikawa K, Sakamoto N.
    Treatment of hepatitis C in special populations.
    J Gastroenterol. 2018 Jan 3. doi: 10.1007/s00535-017-1427-x. [Epub ahead of print] Review. PMID:29299684
  16. Nakai M, Ogawa K, Takeda R, Ohara M, Kawagishi N, Izumi T, Umemura M, Ito J, Sho T, Suda G, Morikawa K, Sakamoto N.
    Increased serum C-reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis.
    Hepatol Res. 2018 Feb;48(3):E311-E319. doi: 10.1111/hepr.12988. Epub 2017 Nov 3.
  17. Osamu Maehara, Goki Suda, Mitsuteru Natsuizaka, Shunsuke Ohnishi, Yoshito Komatsu, Fumiyuki Sato, Masato Nakai, Takuya Sho, Kenichi Morikawa, Koji Ogawa, Tomoe Shimazaki, Megumi Kimura, Ayaka Asano, Yoshiyuki Fujimoto, Shinya Ohashi, Shingo Kagawa, Hideaki Kinugasa, Seiji Naganuma, Kelly A. Whelan, Hiroshi Nakagawa, Koji Nakagawa, Hiroshi Takeda, Naoya Sakamoto(Equal contribution)
    Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma.
    Carcinogenesis. 2017 Oct 26;38(11):1073-1083. doi: 10.1093/carcin/bgx095.
  18. Suda G, Ito J, Nagasaka A, Yamamoto Y, Furuya K, Okamoto M, Terashita K, Kobayashi T, Tsunematsu I, Yoshida J, Meguro T, Ohara M, Kawagishi N, Kimura M, Umemura M, Izumi T, Tsukuda Y, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study.
    Hepatol Res. 2018 Feb;48(3):E146-E154. doi: 10.1111/hepr.12938. Epub 2017 Aug 10.
  19. Goki Suda, Norihiro Furusyo, Hidenori Toyoda, Yoshiiku Kaw
  20. akami, Hiroki Ikeda, Michihiro Suzuki, Keiko Arataki, Nami Mori, Keiji Tsuji, Yoshio Katamura, Koichi Takaguchi, Toru Ishikawa, Kunihiko Tsuji, Noritomo Shimada, Atsushi Hiraoka, Sho Yamsaki, Masato Nakai, Takuya Sho, Kenichi Morikawa, Koji Ogawa, Mineo Kudo, Atsushi Nagasaka, Ken Furuya, Yoshiya Yamamoto, Kanji Kato ,Yoshiyuki Ueno, Etsuko Iio, Yasuhito Tanaka, Masayuki Kurosaki, Takashi Kumada, Kazuaki Chayama and Naoya Sakamoto.
    Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.
    J Gastroenterol. 2018 Jan;53(1):119-128. doi: 10.1007/s00535-017-1353-y. Epub 2017 May 30.
  21. Naoki Kawagishi, Goki Suda, Masahiro Onozawa, Megumi Kimura, Osamu Maehara, Masatsugu Ohara, Takaaki Izumi, Machiko Umemura, Jun Ito, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, and Naoya Sakamoto.
    (Equal contribution). Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.
    J Viral Hepat. 2017 Dec;24(12):1098-1106. doi: 10.1111/jvh.12737
  22. Takuya Sho, Mitsuru Nakanishi, Morikawa Kenichi, Masatsugu Ohara, Naoki Kawagishi, Takaaki Izumi, Machiko Umemura, Jun Ito, Masato Nakai, Goki Suda, Koji Ogawa, Makoto Chuma, Takashi Meguro, Michio Nakamura, Atsushi Nagasaka, Hiromasa Horimoto, Yoshiya Yamamoto, and Naoya Sakamoto.
    A Phase I study of combination therapy with sorafenib and 5-fluorouracil in patients with advanced hepatocellular carcinoma.
    Drugs R D. 2017 Sep;17(3):381-388. doi: 10.1007/s40268-017-0187-7.
  23. Kawagishi N, Suda G, Onozawa M, Kimura M, Maehara O, Ito J, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N (Equal contribution).
    Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection.
    J Hepatol. 2017 Nov;67(5):1106-1108. doi: 10.1016/j.jhep.2017.04.008.
  24. Takahiko Kobayashi, Junich Ishida, Yuichi Shimizu,Hiroshi Kawakami, Goki Suda, Tetsuhito Muranaka, Yoshito Komatsu, Masahiro Asaka and Naoya Sakamoto.
    Decreased RNA-binding motif 5 expression is associated with tumor progression in gastric cancer.
    Tumor Biology. March 2017: 1?9
  25. Suda G, Ogawa K, Yamamoto Y, Katagiri M, Furuya K, Kumagai K, Konno J, Kimura M, Kawagishi N, Ohara M, Umemura M, Ito J, Izumi T, Nakai M, Sho T, Natsuizaka M, Morikawa K, Tsubota A, Shimada N, Iio E, Tanaka Y, Sakamoto N; NORTE Study Group.
    Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
    J Gastroenterol. 2017. Oct;52(10):1122-1129 doi: 10.1007/s00535-017-1328-z.
  26. Suda G, Ogawa K, Kimura M, Nakai M, Sho T, Morikawa K.
    Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment.
    J Clin Transl Hepatol. 2016 Dec 28;4(4):320-327. doi: 10.14218/JCTH.2016.00032. Review.
  27. Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, Kudo M, Terashita K, Kobayashi T, Tsunematsu I, Yoshida J, Meguro T, Kimura M, Ito J, Umemura M, Izumi T, Tsunematsu S, Sato F, Tsukuda Y, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus infected patients with renal impairment.
    Hepatol Res. 2017 Oct;47(11):1127-1136. doi: 10.1111/hepr.12851
  28. Tsukuda Y, Suda G, Tsunematsu S, Ito J, Sato F, Terashita K, Nakai M, Sho T, Maehara O, Shimazaki T, Kimura M, Morikawa K, Natsuizaka M, Ogawa K, Ohnishi S, Chuma M, Sakamoto N.
    Anti-adipogenic and antiviral effects of l-carnitine on hepatitis C virus infection.
    J Med Virol. 2017 May;89(5):857-866. doi: 10.1002/jmv.24692
  29. Tsunematsu S, Suda G, Yamasaki K, Kimura M, Izumi T, Umemura M, Ito J, Sato F, Nakai M, Sho T, Morikawa K, Ogawa K, Tanaka Y, Watashi K, Wakita T, Sakamoto N.
    Hepatitis B virus X protein impairs α-interferon signaling via up-regulation of suppressor of cytokine signaling 3 and protein phosphatase 2A.
    J Med Virol. 2017 Feb;89(2):267-275. doi: 10.1002/jmv.24643.
  30. Seiji Tsunematsu, Goki Suda, Kazushi Yamasaki, Megumi Kimura, Izumi Takaaki, Machiko Umemura, Jun Ito, Fumiyuki Sato, Masato Nakai, Takuya Sho, Kenichi Morikawa, Koji Ogawa, Toshiya Kamiyama, Akinobu Taketomi and Naoya Sakamoto.
    Combination of neutrophil-to-lymphocyte ratio and early des-gamma-carboxyprothrombin change ratio as a useful predictor of treatment response for hepatic arterial infusion chemotherapy against advanced hepatocellular carcinoma.
    Hepatol Res. 2017 May;47(6):533-541doi: 10.1111/hepr.12775. Epub 2016 Aug 11.PMID:27423140
  31. Jun Ito, Goki Suda, Yoshiya Yamamoto, Atsushi Nagasaka, Ken Furuya, Kenichi Kumagai, Hideaki Kikuchi, Takuto Miyagishima, Tomoe Kobayashi, Megumi Kimura, Kazushi Yamasaki, Machiko Umemur, Takaaki Izumi, Seiji Tsunematsu, Fumiyuki Sato, Yoko Tsukuda, Katsumi Terashita, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, and Naoya Sakamoto.
    Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection.
    Hepatol Res. 2016 Dec;46(13):1294-1303. doi: 10.1111/hepr.12685
  32. Morikawa K, Suda G, Sakamoto N.
    Viral life cycle of hepatitis B virus : host factors and druggable targets.
    Hepatol Res. 2016 Aug;46(9):871-7
  33. Suda G, Yamasaki K, Sakamoto N.
    Predictive factors of response to Direct Acting Antivirals therapy, Drug resistance hepatitis C virus.
    Nihon Rinsho. 2015 Dec;73 Suppl 9:189-9
  34. Goki Suda, Mineo Kudo , Atsushi Nagasaka, Ken Furuya, Yoshiya Yamamoto , Tomoe Kobayashi , Keisuke Shinada , Miki Tateyama, Jun Konno, Yoko Tsukuda, Kazushi Yamasaki, Megumi Kimura, Machiko Umemura, Takaaki Izumi, Seiji Tsunematsu, Fumiyuki Sato, Katsumi Terasita, Masato Nakai, Hiromasa Horimoto, Takuya Sho, Mitsuteru Natsuizka, Kenichi Morikawa, Koji Ogawa, and Naoya Sakamoto.
    Efficacy and safety of daclatasvir and asnaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C.
    J Gastroenterol. 2016 Jul;51(7):733-40. doi: 10.1007/s00535-016-1162-8
  35. Suda G, Sakamoto N.
    Progress in Examination and Treatment of Hepatitis C Virus
    Rinsho Byori. 2015 Jun;63(6):762-7.
  36. Maehara O, Sato F, Natsuizaka M, Asano A, Kubota Y, Itoh J, Tsunematsu S, Terashita K, Tsukuda Y, Nakai M, Sho T, Suda G, Morikawa K, Ogawa K, Chuma M, Nakagawa K, Ohnishi S, Komatsu Y, Whelan KA, Nakagawa H, Takeda H, Sakamoto N.
    A pivotal role of Kruppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma.
    Cancer Biol Ther. 2015;16(10):1453-61. doi: 10.1080/15384047.2015.1070992
  37. Fumiyuki Sato, Yoshimasa Kubota, Mitsuteru Natsuizaka, Osamu Maehara, Yutaka Hatanaka, Katsuji Marukawa, Katsumi Terashita, Goki Suda, Shunsuke Ohnishi, Yuichi Shimizu, Yoshito Komatsu, Shinya Ohashi, Shingo Kagawa, Hideaki Kinugasa, Kelly Whelan, Anil Rustgi, Hiroshi Nakagawa, and Naoya Sakamoto.
    EGFR inhibitors eliminate cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition.
    Cancer Biology & Therapy. 2015 2015;16(6):933-40. doi: 10.1080/15384047.2015.1040959
  38. Onishi R, Ohnishi S, Higashi R, Watari M, Yamahara K, Okubo N, Nakagawa K, Katsurada T, Suda G, Natsuizaka M, Takeda H, Sakamoto N.
    Human amnion-derived mesenchymeal stem cell transplantation ameliorates dextran sulfate sodium-induced severe colitis in rats.
    Cell Transplantation. 2015;24(12):2601-2614. Epub 2015 Mar 25
  39. Tsunematsu S1, Chuma M, Kamiyama T, Miyamoto N, Yabusaki S, Hatanaka K, Mitsuhashi T, Kamachi H, Yokoo H, Kakisaka T, Tsuruga Y, Orimo T, Wakayama K, Ito J, Sato F, Terashita K, Nakai M, Tsukuda Y, Sho T, Suda G, Morikawa K, Natsuizaka M, Nakanishi M, Ogawa K, Taketomi A, Matsuno Y, Sakamoto N.
    Intratumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma.
    Abdom Imaging. 2015 Aug;40(6):1492-9. doi:10.1007/s00261-015-0352-
  40. Goki Suda, Yoshiya Yamamoto, Astushi Nagasaka, Ken Furuya, Mineo Kudo, Chuganji Yoshimichi, Yoko Tsukuda, Seiji Tsunematsu, Fumiyuki Sato, Katsumi Terasita, Masato Nakai, Hiromasa Horimoto, Takuya Sho, Mitsuteru Natsuizka, Kouji Ogawa, Shunsuke Ohnishi, Makoto Chuma, Yasuyuki Fujita, Riichiro Abe, Miki Taniguchi, Mina Nakagawa, Yasuhiro Asahina, and Naoya Sakamoto.
    Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions.
    Hepatology Res. 2015 Aug;45(8):837-45. doi: 10.1111/hepr.12421. Epub 2014 Oct 15.
  41. Chuma M, Sakamoto N, Nakai A, Hige S, Nakanishi M, Natsuizaka M, Suda G, Sho T, Hatanaka K, Matsuno Y, Yokoo H, Kamiyama T, Taketomi A, Fujii G, Tashiro K, Hikiba Y, Fujimoto M, Asaka M, Maeda S.
    Heat shock factor 1 accelerates hepatocellular carcinoma development by activating nuclear factor κB/mitogen-activated protein kinase.
    Carcinogenesis. 2014;35(2):272-81 doi: 10.1093/carcin/bgt343 (IF= 5.557)
  42. Seiji Tsunematsu, Mitsuteru Natsuizaka, Hiromi Fujita, Noriyuki Otsuka, Katsumi Terashita, Fumiyuki Sato, Tomoe Kobayashi, Masato Nakai, Yoko Tsukuda, Hiromasa Horimoto, Takuya Sho, Goki Suda, Mitsuru Nakanishi, Satoshi Hashino, Makoto Chuma, Naoya Sakamoto.
    Hepatosplenic Gamma-delta T-cell Lymphoma Associated with Epstein-Barr Virus.
    Intern Med. 2014;53(18):2079-82
  43. Yusuke Funaoka, Naoya Sakamoto, Goki Suda,Mina Nakagawa, Sei Kakinuma , Takako Watanabe, Sayuri Nitta, Akiko Kitazume, Kei Kiyohashi, Miyako Murakawa, Seishin Azuma, Kiichiro Tsuchiya, and Mamoru Watanabe.
    Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91.
    J Virol. 2011; 5986-94.
  44. Goki Suda, Naoya Sakamoto, Yasuhiro Itsui, Mina Nakagawa, Kako Mishima, Yuko Onuki-Karakama, Machi Yamamoto, Yusuke Funaoka, Takako Watanabe, Kei Kiyohashi, Sayuri Nitta, Seishin Azuma, Sei Kakinuma, Kiichiro Tsuchiya, Michio Imamura, Nobuhiko Hiraga, Kazuaki Chayama, and Mamoru Watanabe.
    IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones.
    Virology. 2010; 407:80-90.
  45. Yuki Nishimura-Sakurai, Naoya Sakamoto, Goki Suda et al.
    Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells.
    J Gastroentorol. 2010;45(5):523-536.
  46. Yasuhiro Itsui, Naoya Sakamoto, Sei Kakinuma, Mina Nakagawa, Yuko Sekine-Osajima, Megumi Tasaka-Fujita, Yuki Nishimura-Sakurai, Gouki Suda, Yuko Karakama, Kako Mishima, Machi Yamamoto, Takako Watanabe, Mayumi Ueyama, Yusuke Funaoka, Cheng-Hsin Azuma and Mamoru Watanabe.
    Antiviral effects of the interferon-induced protein GBP-1 and its interaction with the hepatitis C virus NS5B protein.
    Hepatology. 2009; 50:1727-1737.
  47. Sekine-Osajima Y, Sakamoto N, Nakagawa M, Itsui Y, Tasaka M, Nishimura-Sakurai Y, Chen CH, Suda G, Mishima K, Onuki Y, Yamamoto M, Maekawa S, Enomoto N, Kanai T, Tsuchiya K, Watanabe M.
    Two flavonoids extracts from a herb, Glycyrrhizae radix, inhibit in-vitro hepatitis C virus replication.
    Hepatology Res. 2009; 39(1):60-69.
  48. Kubota D, Tajiri K, Mimura S, Suda G, Yui K, Satoh J, Yamamoto C, Watanabe M.
    A case of acute portal and mesenteric venous thrombosis treated with urokinase via superior mesenteric artery.
    Nihon Shokakibyo Gakkai Zasshi. 2005 Feb;102(2):183-9